stockmarket

Exclusive: EU regulators to clear $62 billion Takeda, Shire deal – source


© Reuters. Shire branding is seen outside their offices in Dublin

BRUSSELS (Reuters) – EU antitrust regulators are set to approve Japanese drugmaker Takeda Pharmaceutical’s (T:) $62-billion (47.70 billion pounds) offer for London peer Shire on condition that Shire sells a drug it has in development, a person familiar with the matter said on Friday.

Last month, Takeda offered to divest Shire’s pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





READ SOURCE

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.